These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 29491257)

  • 1. Dihydroorotate Dehydrogenase as a Target for the Development of Novel Helicobacter pylori-Specific Antimicrobials.
    Ohishi T; Inaoka DK; Kita K; Kawada M
    Chem Pharm Bull (Tokyo); 2018; 66(3):239-242. PubMed ID: 29491257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monotherapy with a novel intervenolin derivative, AS-1934, is an effective treatment for Helicobacter pylori infection.
    Ohishi T; Masuda T; Abe H; Hayashi C; Adachi H; Ohba SI; Igarashi M; Watanabe T; Mimuro H; Amalia E; Inaoka DK; Mochizuki K; Kita K; Shibasaki M; Kawada M
    Helicobacter; 2018 Apr; 23(2):e12470. PubMed ID: 29488678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential of fumarate reductase as a novel therapeutic target in Helicobacter pylori infection.
    Ge Z
    Expert Opin Ther Targets; 2002 Apr; 6(2):135-46. PubMed ID: 12223076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of bacterial transglycosylase inhibitors as new antibiotics: moenomycin A treatment for drug-resistant Helicobacter pylori.
    Tseng YY; Liou JM; Hsu TL; Cheng WC; Wu MS; Wong CH
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2412-4. PubMed ID: 24775303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of bacterial and host factors on Helicobacter pylori eradication therapy.
    Uotani T; Miftahussurur M; Yamaoka Y
    Expert Opin Ther Targets; 2015; 19(12):1637-50. PubMed ID: 26245678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Helicobacter pylori-selective antibacterials based on inhibition of pyrimidine biosynthesis.
    Copeland RA; Marcinkeviciene J; Haque TS; Kopcho LM; Jiang W; Wang K; Ecret LD; Sizemore C; Amsler KA; Foster L; Tadesse S; Combs AP; Stern AM; Trainor GL; Slee A; Rogers MJ; Hobbs F
    J Biol Chem; 2000 Oct; 275(43):33373-8. PubMed ID: 10938275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dihydroorotate dehydrogenase inhibitors in anti-infective drug research.
    Boschi D; Pippione AC; Sainas S; Lolli ML
    Eur J Med Chem; 2019 Dec; 183():111681. PubMed ID: 31557612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial resistance in Helicobacter pylori: current situation and management strategy in Vietnam.
    Phan TN; Tran VH; Tran TN; Le VA; Santona A; Rubino S; Paglietti B
    J Infect Dev Ctries; 2015 Jul; 9(6):609-13. PubMed ID: 26142670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
    Vyas VK; Ghate M
    Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel series of human dihydroorotate dehydrogenase inhibitors discovered by in vitro screening: inhibition activity and crystallographic binding mode.
    Zeng T; Zuo Z; Luo Y; Zhao Y; Yu Y; Chen Q
    FEBS Open Bio; 2019 Aug; 9(8):1348-1354. PubMed ID: 31087527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications.
    Gerrits MM; van Vliet AH; Kuipers EJ; Kusters JG
    Lancet Infect Dis; 2006 Nov; 6(11):699-709. PubMed ID: 17067919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Helicobacter pylori and Antibiotic Resistance, A Continuing and Intractable Problem.
    Hu Y; Zhang M; Lu B; Dai J
    Helicobacter; 2016 Oct; 21(5):349-63. PubMed ID: 26822340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection.
    Fiorini G; Vakil N; Zullo A; Saracino IM; Castelli V; Ricci C; Zaccaro C; Gatta L; Vaira D
    Clin Gastroenterol Hepatol; 2013 May; 11(5):507-10. PubMed ID: 23267869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of resistance of Helicobacter pylori to antibiotics on the Helicobacter pylori eradication regimens].
    Cheng H; Hu FL; Li J
    Zhonghua Yi Xue Za Zhi; 2006 Oct; 86(38):2679-82. PubMed ID: 17199976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel and Effective Therapeutic Regimens for
    Hu Y; Zhu Y; Lu NH
    Front Cell Infect Microbiol; 2017; 7():168. PubMed ID: 28529929
    [No Abstract]   [Full Text] [Related]  

  • 16. Dihydroorotate dehydrogenase: A drug target for the development of antimalarials.
    Singh A; Maqbool M; Mobashir M; Hoda N
    Eur J Med Chem; 2017 Jan; 125():640-651. PubMed ID: 27721149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological therapy used in the elimination of Helicobacter pylori infection: a review.
    Dos Santos AA; Carvalho AA
    World J Gastroenterol; 2015 Jan; 21(1):139-54. PubMed ID: 25574087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo treatment of Helicobacter pylori infection with liposomal linolenic acid reduces colonization and ameliorates inflammation.
    Thamphiwatana S; Gao W; Obonyo M; Zhang L
    Proc Natl Acad Sci U S A; 2014 Dec; 111(49):17600-5. PubMed ID: 25422427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Helicobacter pylori resistance to metronidazole and clarithromycin in Brazilian children and adolescents.
    Ogata SK; Godoy AP; da Silva Patricio FR; Kawakami E
    J Pediatr Gastroenterol Nutr; 2013 Jun; 56(6):645-8. PubMed ID: 23403439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation and eradication of a clinical isolate of Helicobacter pylori resistant to five antimicrobials in Germany.
    Wüppenhorst N; Lenze F; Ross M; Kist M
    J Antimicrob Chemother; 2011 Jan; 66(1):222-3. PubMed ID: 21051371
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.